STAAR Surgical Company (STAA) 2026 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings, and welcome to the STAAR Surgical first quarter 2026 results call and webcast. (Operator Instructions)

    各位好,歡迎收聽 STAAR Surgical 2026 年第一季財報電話會議與網路直播。(接線員指示)

  • I would now like to turn the call over to Connie Johnson, Director of Investor Relations.

    現在我想把電話會議交給投資人關係總監 Connie Johnson。

  • Connie Johnson - Director, Investor Relations

    Connie Johnson - Director, Investor Relations

  • Thank you, operator. Good afternoon, and thank you for joining us. On the call today are Warren Foust, Interim Co-CEO, President, and Chief Operating Officer of STAAR Surgical; and Deborah Andrews, Interim Co-CEO and Chief Financial Officer of STAAR Surgical.

    謝謝,接線員。各位下午好,感謝各位加入我們。今天與會者包括:STAAR Surgical 臨時共同執行長、總裁暨營運長 Warren Foust,以及 STAAR Surgical 臨時共同執行長暨財務長 Deborah Andrews。

  • Earlier today, we reported our first quarter of 2026 results via press release and Form 8-K. We posted our results release and shareholder letter to our investor website at investors.staar.com.

    今天稍早,我們已透過新聞稿與 Form 8-K 公布 2026 年第一季業績。我們也已將業績新聞稿與致股東信函發布於投資人網站 investors.staar.com。

  • Today's call is scheduled for 1 hour and will include Q&A for publishing analysts. Webcast participants can also send questions for today's Q&A session to ir@staar.com.

    今天的電話會議預計 1 小時,並將包含提供給發表研究報告之分析師的問答環節。收看網路直播的與會者也可將問題寄至 ir@staar.com,以供今天的問答時段使用。

  • Before we get started, I want to remind you that during today's discussion, we will be making forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. I encourage you to read these disclosures in today's release as well as disclosures in our filings with the SEC. Except as required by law, STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes.

    在開始之前,我想提醒各位,今天的討論中我們將發表前瞻性陳述。前瞻性陳述存在風險與不確定性,可能導致實際結果與該等前瞻性陳述所明示或暗示者有重大差異。我建議各位閱讀今日新聞稿中的相關揭露,以及我們向美國證券交易委員會(SEC)提交文件中的揭露內容。除法律要求外,STAAR 不承擔更新這些前瞻性陳述以反映未來事件或實際結果的義務。

  • In addition, during today's discussion, we will reference certain non-GAAP financial measures, including adjusted EBITDA and constant currency sales. Please refer to today's release for definitions and reconciliations of non-GAAP metrics. For brevity, unless otherwise specified, all comparisons on today's call will be on a year-over-year basis versus the relevant period.

    此外,在今天的討論中,我們將引用若干非 GAAP 財務衡量指標,包括調整後 EBITDA 與固定匯率銷售額。請參閱今日新聞稿中對非 GAAP 指標的定義與調節表。為求簡潔,除非另有說明,今天電話會議中的所有比較均為與相關期間之去年同期相比。

  • Finally, a quick reminder. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the Investor Relations section. Accordingly, investors should monitor our investor website in addition to following our press releases, SEC filings, and public conference calls and webcasts.

    最後,快速提醒一下。我們打算使用公司網站作為揭露重大非公開資訊的方式,並用以遵循《公平揭露規則》(Regulation FD)下的揭露義務。此類揭露將刊載於我們網站的投資人關係(Investor Relations)專區。因此,投資人除關注我們的新聞稿、SEC 申報文件以及公開電話會議與網路直播外,也應持續留意我們的投資人網站。

  • And with that, I'd like to turn the presentation over to the Interim Co-CEO, Warren Foust. Warren?

    接下來,我想把簡報交給臨時共同執行長 Warren Foust。Warren?

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Good afternoon, everyone, and thank you for joining us. Deborah and I are excited to be with you once again and to update you on the progress that we have made in our first 100-or-so days since we began leading the company as interim Co-CEOs. I'm really happy to talk about Q1 of 2026 as we have now largely moved past many of the challenges that we faced in 2025. Significant disruptions stemming from the potential Alcon merger process, elevated channel inventory in our largest market, and risks of rising tariffs, to name a few. Those issues are behind us.

    各位下午好,感謝各位加入我們。Deborah 和我很高興再次與各位相聚,並向各位更新自我們以臨時共同執行長身分開始領導公司以來約 100 天所取得的進展。我很高興談到 2026 年第一季,因為我們現在已大致走出 2025 年面臨的許多挑戰。例如:潛在與愛爾康(Alcon)合併流程所帶來的重大干擾、我們最大市場通路庫存偏高,以及關稅上升風險等。這些問題都已成為過去。

  • Now, turning to Q1. We see that we’re off to a very positive start as reflected in our first-quarter results. I would point to solid execution across the business and continued momentum broadly across our key markets. We made substantial advancements in pursuit of our core objectives, in particular relative to revenue growth and expansion of our profitability. We remain focused on these efforts, as well as working to strengthen our product portfolio and developing our next-generation pipeline.

    接著談第一季。從第一季業績可見,我們有一個非常正面的開局。我會將其歸因於全公司穩健的執行力,以及我們主要市場普遍延續的動能。我們在推進核心目標方面取得重大進展,特別是在營收成長與獲利能力提升擴張方面。我們將持續聚焦這些工作,同時也致力於強化產品組合並開發下一代產品管線。

  • In the first quarter, we delivered strong net sales growth, both sequentially and year over year. We also delivered a meaningful improvement in profitability in the quarter, with adjusted EBITDA turning positive. This performance was driven primarily by strong results in China, our first greater than $6 million quarter in the United States, and solid growth from each of our three regions. We were also excited to reach a significant milestone, surpassing 4 million ICLs sold globally.

    第一季,我們的淨銷售額無論與前一季相比或與去年同期相比,皆呈現強勁成長。本季獲利能力也顯著改善,調整後 EBITDA 轉為正值。此表現主要受中國強勁成果、美國單季首次突破 600 萬美元,以及三大區域各自穩健成長所帶動。我們也很高興達成一項重要里程碑:全球 ICL 累計銷售量突破 400 萬片。

  • I’m proud of our committed teams and distribution partners around the world who are driving revenue growth.

    我為我們遍布全球、全心投入的團隊與經銷合作夥伴感到自豪,他們正推動營收成長。

  • At the same time, we are maintaining spending discipline and improving profitability through focused execution. I believe that our results are an early indication that our approach is beginning to work.

    同時,我們維持支出紀律,並透過聚焦執行來提升獲利能力。我相信,我們的業績是早期跡象,顯示我們的方法正開始奏效。

  • Beyond the financial results, the quarter also included several important business milestones that reinforce our confidence in STAAR’s long-term opportunity. First, we made further advancements in the launch of EVO+ ICL in China and began shipping meaningful volumes into the market. Second, we entered Q1 with inventory levels in China normalized and aligned with our contractual targets, and we were able to grow sales while maintaining and even slightly reducing inventory levels during the quarter.

    除了財務表現之外,本季也包含數項重要的業務里程碑,進一步強化我們對 STAAR 長期機會的信心。第一,我們在中國推進 EVO+ ICL 上市方面取得更多進展,並開始向市場出貨具規模的數量。第二,我們在第一季開始時,中國的庫存水位已正常化並與合約目標一致;而且我們在本季維持甚至略為降低庫存水位的同時,仍能推動銷售成長。

  • Third, our Nidau, Switzerland manufacturing facility continues to scale and is planned in 2026 to supply 100% of the EVO and EVO+ lenses shipped to China without import tariffs. And finally, we are progressing through the rollout of our new Oracle ERP system with limited business disruption to date and expected benefits in visibility, coordination, and scalability over time. Together, these milestones are important because they support both our near-term execution and our longer-term ability to scale the business more efficiently.

    第三,我們位於瑞士 Nidau 的製造廠持續擴產,並計畫於 2026 年供應運往中國之 EVO 與 EVO+ 鏡片的 100%,且不需承擔進口關稅。最後,我們正推進新 Oracle ERP 系統的導入與上線,目前為止對營運造成的干擾有限,並預期隨時間推進可在可視性、協同與可擴展性方面帶來效益。綜合而言,這些里程碑之所以重要,是因為它們同時支撐我們的短期執行,以及我們長期更有效率擴大營運規模的能力。

  • Let me now provide more context on China, which was the primary driver of our first quarter and remains a key focus area for STAAR. In China, our first-quarter performance reflected continued share gains in premium lens-based refractor surgery. The key messages were clear: continued strength in EVO ICLs, strong early demand for EVO+ ICLs, normalized inventory levels, better downstream visibility, and a more stable market environment. Refractive market conditions in China were more stable in the first quarter than during the volatile period from 2022 to 2024.

    接下來我將就中國市場提供更多背景說明。中國是我們第一季的主要成長動能來源,也仍是 STAAR 的關鍵聚焦領域。在中國,我們第一季的表現反映出在高端晶體型屈光手術領域持續提升市占率。關鍵訊息很明確:EVO ICL 持續強勁、EVO+ ICL 早期需求強勁、庫存水位正常化、下游能見度更佳,以及更穩定的市場環境。中國屈光市場在第一季的狀況較 2022 至 2024 年的波動期間更為穩定。

  • The macroenvironment remains mixed, but based on what we are seeing and hearing from customers, refractive procedure demand continues to grow at a moderate pace. We are encouraged by our team’s performance in Q1 and the early response to EVO+, an important step in our innovation strategy where strong surgeon adoption and clinical differentiation have already required higher output from our Swiss manufacturing site.

    總體環境仍然好壞參半,但根據我們從客戶端看到與聽到的情況,屈光手術需求仍以溫和速度成長。我們對團隊第一季的表現以及市場對 EVO+ 的早期回饋感到鼓舞;這是我們創新策略中的重要一步,外科醫師的高度採用與臨床差異化已使我們瑞士製造基地需要提高產出。

  • Moving forward, we remain focused on disciplined execution and sustaining this momentum over the course of the year while carefully monitoring macroeconomic factors in the market. Now, as we look at the United States, we are encouraged by our first-quarter sales that exceeded $6 million, and we continue to view this market as an important long-term growth opportunity for STAAR. We also received FDA approval expanding the EVO ICL indication to patients aged 45 to 60, further increasing our addressable market.

    展望未來,我們仍將專注於有紀律的執行,並在全年持續維持這股動能,同時審慎監測市場中的總體經濟因素。再看美國市場,我們對第一季銷售額超過 600 萬美元感到鼓舞,並持續將此市場視為 STAAR 重要的長期成長機會。我們也獲得 FDA 核准,將 EVO ICL 的適應症擴大至 45 至 60 歲患者,進一步提升我們的可服務市場規模。

  • Net sales grew 22% year over year against a backdrop of continued sluggishness of laser vision correction procedures that require removal of corneal tissue. The continued adoption of EVO ICL reinforces our belief that the future of refractive surgery is largely lens-based. We believe our performance reflects increased surgeon adoption, improved commercial execution, and a more focused marketing strategy around customers who are incorporating EVO ICL more meaningfully into their refractive offerings.

    在需要移除角膜組織的雷射視力矯正手術持續低迷的背景下,淨銷售額年增22%。EVO ICL 的持續採用強化了我們的信念:屈光手術的未來在很大程度上將以晶體為基礎。我們認為,我們的表現反映了外科醫師採用度提升、商業執行改善,以及更聚焦於將 EVO ICL 更有意義地納入其屈光產品組合之客戶的行銷策略。

  • The US remains under-penetrated relative to more mature ICL markets, which is why we continue to view it as an important long-term growth opportunity. Outside China and the US, several markets experienced geopolitical and trade-related disruption during the quarter, particularly in parts of the Middle East. The impact on net sales was limited to less than $2 million. We continue to monitor these developments closely, along with the broader macro uncertainty in Europe and in parts of Asia.

    相較於較成熟的 ICL 市場,美國市場的滲透率仍偏低,這也是我們持續將其視為重要長期成長機會的原因。除中國與美國之外,本季多個市場出現地緣政治與貿易相關的干擾,尤其是在中東部分地區。對淨銷售額的影響有限,不到200萬美元。我們將持續密切關注這些發展,以及歐洲與亞洲部分地區更廣泛的總體不確定性。

  • We also continue to see attractive long-term opportunities in markets such as India, even though near-term price sensitivity and macro volatility require a measured approach. More broadly, as we pursue global growth opportunities, we are being disciplined in how we allocate capital and resources. We are prioritizing markets and commercial programs where we see the strongest potential while continuing to benefit from the cost reduction efforts we initiated in 2025. As sales grow, we expect this approach to support operating leverage going forward.

    我們也持續在印度等市場看到具吸引力的長期機會,儘管短期的價格敏感度與總體波動需要採取審慎的方式。更廣泛而言,在我們追求全球成長機會的同時,我們在資本與資源配置上保持紀律。我們將優先投入在我們認為潛力最強的市場與商業計畫,同時持續受益於我們在2025年啟動的成本降低措施。隨著銷售成長,我們預期此作法將在未來支撐營運槓桿。

  • Overall, our view is unchanged. The global shift toward lens-based refractive surgery remains a meaningful long-term growth driver for STAAR. Taken together, these updates reflect the progress we are making commercially and operationally while maintaining the discipline needed to build more consistent performance over time.

    整體而言,我們的觀點不變。全球朝向以晶體為基礎的屈光手術轉移,仍是 STAAR 具意義的長期成長驅動力。綜合來看,這些更新反映了我們在商業與營運面所取得的進展,同時也維持建立更一致表現所需的紀律。

  • With that, I’ll turn the call over to Deborah to walk through the financials in more detail. Deborah?

    接下來,我把電話交給 Deborah,請她更詳細地說明財務狀況。Deborah?

  • Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

    Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

  • Thank you, Warren. Our first-quarter results reflect strong execution across both sales growth and profitability, consistent with the framework we outlined in our fourth quarter shareholder letter. Net sales were $93.5 million, increasing 119.6% year over year, driven by strong China sales and double-digit growth in the Americas. China net sales were $47.4 million in the first quarter, driven by the commercial launch of EVO+ and continued demand for EVO.

    謝謝你,Warren。我們第一季的結果反映了在銷售成長與獲利能力兩方面的強勁執行力,與我們在第四季股東信中所概述的架構一致。淨銷售額為9,350萬美元,年增119.6%,主要由中國強勁銷售以及美洲地區的雙位數成長所帶動。第一季中國淨銷售額為4,740萬美元,受 EVO+ 的商業上市以及 EVO 持續需求所驅動。

  • Distributor inventory remained comparable to year-end 2025 levels and within our targeted range to appropriately service the refractive market. Excluding China, net sales grew 6%, which we view as solid given the macroeconomic environment.

    經銷商庫存水準與2025年年底相當,且維持在我們的目標區間內,以適當服務屈光市場。排除中國後,淨銷售額成長6%,考量總體經濟環境,我們認為表現穩健。

  • First quarter net sales were bolstered by a solid quarter in the US market despite the downtrend in laser vision correction in the country, partially offset by macroeconomic and geopolitical headwinds in the Middle East and India. Adjusted EBITDA was $24.4 million compared to an adjusted EBITDA loss of $26.3 million in the prior-year quarter, reflecting higher net sales, improved gross profit, and the benefits of the cost actions we’ve implemented since 2025. We are beginning to see operating leverage emerge consistent with our path to sustainable profitability.

    第一季淨銷售額受惠於美國市場表現穩健,儘管該國雷射視力矯正呈下降趨勢;但部分被中東與印度的總體經濟與地緣政治逆風所抵銷。調整後 EBITDA 為2,440萬美元,相較去年同期調整後 EBITDA 虧損2,630萬美元,反映淨銷售額提高、毛利改善,以及自2025年以來我們所實施成本措施的效益。我們開始看到營運槓桿浮現,符合我們邁向可持續獲利的路徑。

  • Gross profit margin in the first quarter of 2026 was 73.6% of total net sales compared to 65.8% in the prior-year quarter. The year-over-year improvement was primarily driven by the elimination of period costs related to the ramp-up of manufacturing in Switzerland, a reduction in advanced manufacturing expenses, lower inventory provisions, and decreased freight and other cost of sales as a percentage of sales. These benefits were partially offset by higher per unit manufacturing costs resulted from lower production volumes in 2025.

    2026年第一季毛利率為淨銷售額的73.6%,相較去年同期為65.8%。年增改善主要來自:消除與瑞士製造產能爬坡相關的期間成本、先進製造費用降低、存貨提列減少,以及運費與其他銷貨成本占銷售比重下降。上述效益部分被2025年較低產量所導致的單位製造成本上升所抵銷。

  • Total operating expenses for the first quarter of 2026 were $60.9 million compared to $85.4 million in the prior-year quarter. Excluding restructuring and merger-related costs, operating expenses were $51.5 million compared to $62.7 million in the prior-year quarter, a decrease of 18% year over year, reflecting the cost reduction efforts initiated in 2025 and continued spending discipline. The company remains on track with its spending target of $225 million in 2026.

    2026年第一季總營業費用為6,090萬美元,去年同期為8,540萬美元。排除重組與併購相關成本後,營業費用為5,150萬美元,去年同期為6,270萬美元,年減18%,反映2025年啟動的成本降低措施以及持續的支出紀律。公司仍按計畫達成2026年2.25億美元的支出目標。

  • Operating income for the first quarter of 2026 was $8 million compared to a loss of $57.4 million in the prior-year quarter. Net income for the first quarter of 2026 was $5.2 million, or $0.10 per diluted share, compared to a net loss of $54.2 million, or $1.10 per diluted share in the prior-year quarter. The year-over-year improvement net income was primarily attributable to higher gross profit and lower operating expenses, demonstrating our ability to grow net sales while maintaining spending discipline. We ended the quarter with $163.9 million in cash, cash equivalents, and investments available for sale with no outstanding debt.

    2026年第一季營業利益為800萬美元,去年同期為虧損5,740萬美元。2026年第一季淨利為520萬美元,稀釋後每股盈餘0.10美元;去年同期為淨損5,420萬美元,稀釋後每股虧損1.10美元。淨利年增改善主要歸因於毛利提高與營業費用降低,展現我們在維持支出紀律的同時提升淨銷售額的能力。本季末我們持有現金、約當現金及可供出售投資合計1.639億美元,且無任何未償債務。

  • On a sequential basis, cash declined from the fourth quarter of 2025, primarily due to costs including seasonal bonuses and other employee incentives, global sales meetings, severance, and costs associated with the cooperation agreement with Broadwood Partners. With these items now behind us, we expect to build cash throughout the remainder of the year.

    以季比而言,現金較2025年第四季下降,主要由於季節性獎金與其他員工激勵、全球銷售會議、資遣費,以及與 Broadwood Partners 合作協議相關成本等支出。隨著這些項目已告一段落,我們預期在今年剩餘期間將逐步累積現金。

  • Overall, we are encouraged by the profitability and operating leverage demonstrated by our first-quarter results. We remain focused on balancing growth with disciplined investment and maintaining financial flexibility.

    整體而言,我們對第一季結果所展現的獲利能力與營運槓桿感到鼓舞。我們仍專注於在成長與有紀律的投資之間取得平衡,並維持財務彈性。

  • With that, I’ll turn the call back over to Warren. Warren?

    接下來,我把電話交回給 Warren。Warren?

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Thank you, Deborah. To close, Q1 was a strong quarter. It demonstrates the progress we are making toward building a stronger STAAR with differentiated technology, greater operating discipline, and a clearer path to sustainable growth and profitability. We believe STAAR is better positioned today than it was entering the year.

    謝謝你,Deborah。最後,第一季表現強勁。這展現了我們在打造更強大的 STAAR 方面所取得的進展:具差異化的技術、更高的營運紀律,以及更清晰的可持續成長與獲利路徑。我們相信,STAAR 目前的定位比年初時更佳。

  • In the quarter, we demonstrated strong growth, return to profitability, improved adjusted EBITDA margins, and operational improvements. We launched EVO+ ICL in China, advanced our Swiss manufacturing capabilities, continued the rollout of our Oracle ERP, and strengthened our cost structure. At the same time, our long-term opportunity remains compelling. STAAR possesses differentiated polymer material and advanced optical technology in EVO ICL. Additionally, we see growing global adoption within a large market supported by increasing myopia prevalence and a shift toward lens-based refractive surgery.

    本季我們展現了強勁成長、重返獲利、調整後 EBITDA 利潤率改善,以及營運面改善。我們在中國推出 EVO+ ICL,推進瑞士製造能力,持續推動 Oracle ERP 的導入,並強化成本結構。同時,我們的長期機會仍具吸引力。STAAR 在 EVO ICL 上擁有具差異化的聚合物材料與先進光學技術。此外,在近視盛行率上升以及屈光手術轉向以晶體為基礎的趨勢支持下,我們看到在龐大市場中全球採用度持續提升。

  • Now, our focus is to build on this momentum against our core objectives, revenue growth, expanding profitability, and advancing innovation. Deborah and I are aligned with our Board and focused on long-term value creation through clear priorities and operating discipline. Thank you for your continued support.

    目前,我們的重點是在核心目標上延續這股動能:營收成長、擴大獲利能力,以及推進創新。Deborah 與我與董事會立場一致,並透過明確的優先事項與營運紀律,專注於創造長期價值。感謝各位持續的支持。

  • Operator, we are now ready to take questions.

    接線員,我們現在準備開始接受提問。

  • Operator

    Operator

  • (Operator Instructions) John Young, Canaccord Genuity.

    (接線員指示) John Young,Canaccord Genuity。

  • John Young - Equity Analyst

    John Young - Equity Analyst

  • Congratulations on the progress that you guys have been making. I appreciate you guys are not giving guidance right now, but I first wanted just to touch on just consensus into the frame was $311 million to $12 million. Are you comfortable with that figure?

    恭喜你們在進展上取得的成果。我理解你們目前不提供財測指引,但我首先想先談一下,市場共識在這個區間是3.11億美元到3.12億美元。你們對這個數字感到安心嗎?

  • And then just as a follow-up too, on China what is the confidence that you have in the Q2 high season, just given the Q1 success that you’ve seen so far? Would sequentially flat Q2 China revenue be a good way to think about next quarter? Thanks for taking the questions.

    另外再追問一下,關於中國市場,考量到你們目前看到的第一季成功表現,你們對第二季旺季的信心如何?若以中國第二季營收較第一季持平(按季持平)來思考下一季,會是合理的看法嗎?謝謝讓我提問。

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Yeah. Hey, John. Thanks for the question, I appreciate both of them. Look, we understand why you’d want guidance. Historically, Q1’s been really strong, and we’re proud of the Q1 performance. What’s happened in the past is you’ve seen a tendency for the high season to maybe not show up in this period of '22 to 2024 where things were a little softer. So we’re optimistic, but we’re just not ready at this point to say, hey, we’re certain about everything that’s going to happen downstream with all of the stuff that’s going on macroeconomically and geopolitically, not just in China, but elsewhere.

    是的。嗨,John。謝謝你的問題,我很感謝這兩個問題。我們理解你為什麼會想要指引。歷史上第一季一直很強,我們也為第一季的表現感到自豪。過去的情況是,在2022到2024這段期間,因為整體較疲弱,你會看到旺季可能沒有如期出現的趨勢。所以我們是樂觀的,但在目前這個時間點,我們還沒準備好說:在當前宏觀經濟與地緣政治的各種變數下,我們能對後續所有事情都完全確定——不只是中國,其他地區也是如此。

  • A couple of wars going on, a couple of challenges going on in various markets relative to currency. We’re just not ready to do that, so I can’t comment on the 311 to 312.

    目前有幾場戰爭在進行,也有一些市場在匯率方面面臨挑戰。我們還沒準備好做到那一步,所以我無法評論3.11億到3.12億這個區間。

  • As it pertains to China, look, the market, you’ve seen reports from our biggest customer there that the refractor market seems more stable than it’s been. We certainly saw that as we went out of 2025, and I think Q1, we’re pleased so far with where we are, and let’s see what the high season brings, but we’ll certainly be ready for it as if the high season comes.

    至於中國方面,你也看到我們在那裡最大的客戶所發布的報告,屈光市場看起來比以往更穩定。我們在2025年末時確實也看到這點,而我認為第一季到目前為止,我們對現況感到滿意;接下來就看看旺季會帶來什麼,但如果旺季真的到來,我們一定會做好準備。

  • Operator

    Operator

  • Tom Stephan, Stifel.

    Tom Stephan,Stifel。

  • Thomas Stephan - Analyst

    Thomas Stephan - Analyst

  • Congrats on the results here. I’ll start off on China competition. Warren, maybe if you can talk about what you’re seeing in China from a competitive standpoint with Eyebright. How big has that gotten in its first 12-plus months in the market? And what are your expectations moving forward on Eyebright’s impact as well as potential additional China phakic IOLs on the come? And then I’ll have a follow-up.

    恭喜這次的業績表現。我先從中國的競爭談起。Warren,也許你可以談談你們在中國看到的競爭態勢,特別是來自Eyebright的部分。它在進入市場的前12個多月,規模成長到多大?以及你們對未來Eyebright的影響、以及可能還會有其他中國的有晶體眼內鏡(phakic IOL)產品推出的看法是什麼?我之後還有一個追問。

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Yeah. Hey, Tom. Thanks for the question. Look, we love the idea of competition. It just further validates our view that the future of lens-based refractive surgery is exactly that. It’s lens-based and we stand to gain from that. So good to have competition.

    好的。嗨,Tom。謝謝你的問題。我們其實很喜歡競爭這件事。這會進一步驗證我們的觀點:以人工晶體為基礎的屈光手術的未來,正是如此。它是以晶體為基礎,而我們也將從中受益。所以有競爭是好事。

  • As it pertains to Eyebright we see them. We know that there were some implants that happened early on, and I think surgeons are probably taking a measured approach. There’s no Toric available, so it’s a sphere-only lens. We respect them as competitors, but thus far it’s just been a non-issue for us.

    至於Eyebright,我們有在關注他們。我們知道他們在早期確實有一些植入案例,我想外科醫師可能也在採取較為審慎的方式。他們目前沒有散光(Toric)版本,所以只有球面鏡片。我們尊重他們作為競爭對手,但到目前為止,對我們而言並沒有造成影響。

  • Thomas Stephan - Analyst

    Thomas Stephan - Analyst

  • Got it. Super helpful. And then I’ll take a stab at the revenue outlook here. But I mean, I look at 1Q, it seems like it was a normal quarter by all accounts, really, notably from an inventory standpoint. And in fact, I think you mentioned it was down sequentially.

    了解。非常有幫助。接著我想試著問一下營收展望。我看第一季,從各方面來看似乎是一個正常的季度,尤其是在庫存方面相當明顯。而且我記得你們提到庫存是按季下降的。

  • So my question is like for us, is it fair to use 1Q as a clean base and think about typical seasonality in the business for 2Q and moving forward? For 2Q specifically, as you mentioned, it usually sees a pretty meaningful sequential uptick driven by China. Like is there anything that would prevent that from occurring?

    所以我的問題是:對我們來說,是否可以把第一季當作一個乾淨的基期,並以業務的典型季節性來思考第二季以及之後的走勢?就第二季而言,如你們所提到,通常會因中國帶動而出現相當明顯的按季成長。是否有任何因素會阻止這種情況發生?

  • And yeah, I guess the heart of my question, like is 1Q kind of a clean base off which we can think about modeling the rest of the year on revs? Thanks, guys.

    是的,我想我問題的核心是:第一季是否算是一個乾淨的基期,讓我們可以用來建模今年剩餘時間的營收?謝謝各位。

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Yeah, you bet. Maybe I’ll start and then invite Deborah to round out the comments. Look, I think, we know that last year there was a little bit of pull forward in the first quarter relative to military procedures and things of that nature. We don’t participate in those procedures in China, there’s somewhat potentially of a halo effect where you get clinics out that are recruiting for these patients to come to their clinics. And certainly, those patients that could end up being candidates for EVO ICL could get it. So we’ll see if that’s a repeat as we go into the second quarter here.

    好的,沒問題。也許我先回答,然後請Deborah補充完整。我們知道去年第一季相較之下有一些提前拉貨(pull forward),與軍方手術等類似事項有關。我們不參與中國的那些手術,但可能會有某種光環效應(halo effect):有些診所會外出招募這些病患到他們的診所。而這些病患中,確實可能有人最後會成為EVO ICL的候選者並接受植入。所以我們會觀察在進入第二季時,這種情況是否會再度出現。

  • As far as seasonality, students are still going graduate from college. Their parents are still going to want them to get out of glasses and contacts. Those people that could become patients will evaluate their options, and we think and see that increasingly folks are choosing EVO ICLs.

    就季節性而言,學生仍然會從大學畢業。他們的父母仍然會希望他們不再戴眼鏡和隱形眼鏡。那些可能成為病患的人會評估各種選項,而我們認為、也看到越來越多人選擇EVO ICL。

  • Now, what that’s going to mean from a seasonality standpoint, hard to say. It is true that typically June and July are higher months if you look back in history. We just can’t say yet that we think that’s going to be the case. Again, the strength in Q1 is real. Let’s see what Q2 brings. But Deborah, anything to add?

    至於這對季節性意味著什麼,現在還很難說。確實,如果回顧歷史,6月和7月通常是較高的月份。但我們目前還不能說我們認為今年一定會如此。同樣地,第一季的強勁表現是真實的。讓我們看看第二季會帶來什麼。不過Deborah,你有要補充的嗎?

  • Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

    Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

  • No, I think we’re optimistic about the future. We expect to have a good Q2. The results of Q3 remain to be seen yet. And so, we’re kind of cautious about our giving guidance or anything like that, at least in the short term. And we’ll revisit it later on in the year.

    沒有,我認為我們對未來是樂觀的。我們預期第二季會有不錯的表現。第三季的結果仍有待觀察。因此,至少在短期內,我們對提供指引或類似事項會比較謹慎。我們會在今年稍晚再重新評估。

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • And I will just say to your question about it being the first clean quarter. Look, we had a lot of noise in 2025 and even back to the end of 2024 relative to the things that happened with inventory and the timing of recognizing the revenue and the timing of recognizing COGS associated with it. As I said in my prepared remarks, all that stuff is now out of the system.

    另外我也回應你關於「是否為第一個乾淨季度」的問題。你看,2025年以及甚至回到2024年末,我們在庫存相關事項上有很多雜訊,包括認列營收的時點、以及與之相關的銷貨成本(COGS)認列時點。如我在事先準備的發言中所說,這些事情現在都已經從系統中消化完畢。

  • In market demand, which is really important, and we monitor it closely, we said at the end of 2025, we think it was in that mid-single-digit range. We’ve said today, and I think that we’ve seen Aier and even others that have reported, the refractive market in China seems somewhat stable.

    就市場需求而言,這確實非常重要,我們也密切監控。我們在2025年底曾表示,我們認為需求大約落在中個位數百分比的區間。我們今天也提到,而且我認為我們也看到愛爾以及其他已經公布的公司,中國的屈光市場似乎相對穩定。

  • Now, is that -- are we all really excited about that? Want the refractive market to continue to grow. We’re excited about the fact that EVO seems to be taking share in a refractive market where laser vision correction that requires the removal of corneal tissue is sort of coming out of favor.

    那麼,這是否——我們真的都對此感到非常興奮嗎?我們希望屈光市場能持續成長。我們感到振奮的是,在一個需要切除角膜組織的雷射視力矯正逐漸不再受青睞的屈光市場中,EVO 似乎正在取得市占。

  • Operator

    Operator

  • Simran Kaur, Wells Fargo.

    Simran Kaur,富國銀行。

  • Simran Kaur - Analyst

    Simran Kaur - Analyst

  • Maybe just to follow up on the Q1 China numbers here. I know Warren and Deborah, you guys talked about sort of the Q4 being a little bit noisy due to product returns that you had in the distribution channel. And that dynamic would have normalized post the deal and sort of that noise abating.

    也許只是跟進一下這裡第一季中國的數字。我知道 Warren 和 Deborah,你們提到第四季因為通路中的產品退貨,數字有點雜訊。而在交易完成後,那個動態應該已經正常化,相關雜訊也逐步消退。

  • So I guess my question is, did that dynamic reverse in Q1? And how much of the Q1 China revenue represents post-deal makeup orders for the Q4 shortfall? And really just trying to understand what a clean Q1 China run rate is here. I have a follow-up.

    所以我想問的是,那個動態在第一季是否反向發生了?第一季中國營收中,有多少是交易完成後為彌補第四季缺口而下的補單?我主要是想了解,若排除雜訊,第一季中國的乾淨 run rate 大概是多少。我還有一個追問。

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Okay, thanks, Simran. We talk about inventory here every day. If not every day, it’s every week for sure. We’re monitoring closely what’s happening with end-market demand. And so we know what the inventory levels were as we crossed the threshold into 2026.

    好的,謝謝你,Simran。我們每天都在談庫存。就算不是每天,也肯定是每週都在談。我們正密切監控終端市場需求的變化。因此,我們很清楚在跨入2026年時的庫存水位是多少。

  • And at the end of the quarter, we posted a solid number in China, and that inventory level with our distributors and the two importers that we have in China was at or below the levels that we entered the year. And so, we know that the end-market demand is what’s driving the sales. So we feel good about that, and we’ll continue to watch that. You can rest assured and count on us for that.

    而在季末,我們在中國繳出一個穩健的數字;我們在中國的經銷商以及兩家進口商的庫存水位,與年初相比持平或更低。因此,我們知道是終端市場需求在驅動銷售。所以我們對此感到放心,也會持續觀察。你可以放心,我們一定會持續把關。

  • Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

    Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

  • And we also were pleased to see that our sales to the market approximated the sales into the market, and that’s what we’ve been wanting to see, stable inventory with our sales to the market approximating sales in the market.

    另外,我們也很高興看到,我們對市場的出貨量大致接近市場端的銷售量,這正是我們一直希望看到的:經銷端庫存穩定,且我們對市場的出貨量大致貼近市場端的實際銷售量。

  • Simran Kaur - Analyst

    Simran Kaur - Analyst

  • And just on EVO+, I think if I heard your comments correctly, you said early EVO+ demand exceeded expectations here in Q1. Any color on what EVO+ represented as a percentage of Q1 China revenue? And how should we think about the volume price mix benefit from EVO+ in Q1 and then just going forward as it starts to ramp?

    再談 EVO+,如果我沒聽錯你的意思,你說第一季初期的 EVO+ 需求超出預期。能否補充一下,EVO+ 約占第一季中國營收的百分比是多少?以及我們該如何看待第一季 EVO+ 帶來的量價組合(volume/price mix)效益,並且在未來隨著它開始放量時又會如何?

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Yeah. Look, we’ve been excited about the customers’ reaction around EVO+, not just our surgeons, but consumer interest in EVO+. So that’s exciting.

    是的。你看,我們對客戶對 EVO+ 的反應感到很興奮,不只是我們的手術醫師,消費者對 EVO+ 的興趣也很高。所以這很令人振奮。

  • Remember that all of that product comes out of our Swiss manufacturing plant in Nidau. And to do that, we’re having to, and have had to scale that plant to be able to not only build V5 or EVO+, but ultimately to be able to build EVO, the original version, we call it V4C, but EVO for our customers in China. The reality is we needed more V5 than we had planned to produce. So that’s a good fact.

    請記得,所有這些產品都來自我們位於瑞士 Nidau 的製造工廠。為了做到這點,我們必須、而且也已經在擴充該工廠的產能,使其不僅能生產 V5 或 EVO+,最終也能為中國客戶生產 EVO 的原始版本——我們稱之為 V4C,但對客戶而言就是 EVO。現實是,我們需要的 V5 產量比原先規劃的更高。所以這是一個好現象。

  • We’ll have that under control very soon. So we think we’ll be able to supply the market fully against its needs by the end of the Q2 timeframe and for the rest of the year. And by the rest of the year -- for the rest of the year, we should be able to supply both EVO+ and EVO out of our Swiss manufacturing plant. So that’s all good.

    我們很快就會把這件事控制好。因此,我們認為在第二季末的時間點之前,以及今年剩餘期間,我們將能夠充分供應市場需求。而且在今年剩餘期間——我們應該能夠從瑞士工廠同時供應 EVO+ 與 EVO。所以整體來說都很正面。

  • As far as the ratio, we’re not sharing those numbers yet, but what I would offer you is we know that the market has adopted and accepted the premium that EVO+ is requiring. And so, that’s a good thing. It also means that the customers in China have taken a pricing strategy to be able to offer a more premium EVO+, still offering a higher price premium EVO, and that goes along with our other refractive offerings. And so you’re not going to see a full conversion strategy to V5, to EVO+. You’re going to see surge customers continue to use that product as their most premium product.

    至於比例,我們目前還不分享那些數字;但我可以提供的是,我們知道市場已經採用並接受 EVO+ 所要求的溢價。因此,這是好事。這也意味著,中國客戶採取了一套定價策略:提供更高端的 EVO+,同時仍保留價格更高、屬於高端溢價的 EVO,並與我們其他屈光產品組合相互搭配。因此,你不會看到一個全面轉換到 V5、轉換到 EVO+ 的策略。你會看到部分客戶持續把該產品作為他們最頂級的產品來使用。

  • Operator

    Operator

  • (Operator Instructions) Anthony Petrone, Mizuho Group.

    (接線員指示)Anthony Petrone,瑞穗集團。

  • Anthony Petrone - Analyst

    Anthony Petrone - Analyst

  • Congrats on a strong quarter here. Maybe, a follow-up on China from two angles. One is specifically from Aier Eye Care Group, that's a few years back when we looked at the volume specifically in China. I think, free the correction, Aier was accounting for 50% or so of volumes in China. So want to confirm where Aier is these days and what is the visibility into their procedure backlog specifically? And then I’ll have one quick follow-up.

    恭喜本季表現強勁。我想從兩個角度追問一下中國。第一個是關於愛爾眼科集團,幾年前我們看中國的量時,如果我沒記錯,愛爾大約占中國量的50%左右。所以想確認一下愛爾目前的情況,以及對他們手術待消化量(procedure backlog)的可見度如何?然後我還有一個簡短的追問。

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Yeah, Anthony, it’s a good question. It’s not quite that high. I don’t think we’ve revealed exactly what that is, so I’ll stop short there. But Aier remains a very large, very important customer for us in China. We have close working relationships with them on the ground from our direct STAAR employees, and we have close working relationships with them through our importer.

    是的,Anthony,這是個好問題。其實沒有那麼高。我不認為我們已經公開揭露確切數字,所以我就先不往下說。但愛爾仍然是我們在中國非常大、非常重要的客戶。我們在當地透過 STAAR 的直屬員工與他們保持密切合作關係,也透過我們的進口商與他們維持緊密合作。

  • So we maintain proximity to them on an all-the-time basis. They seem to have high appetite to continue having a premium offering. They have high appetite for EVO+. But our strong quarter was really driven by continued adoption of EVO at mid and high diopters. And so, I think they continue to run a well-rounded business. It plays an important part of our existing and our future business in China, and the relationship with them is very strong.

    因此,我們一直都與他們保持非常近的距離。他們似乎很有意願持續提供高端產品。他們對 EVO+ 的需求也很高。但我們這一季的強勁表現,主要是由 EVO 在中度與高度屈光度(diopters)的持續採用所驅動。因此,我認為他們仍在經營一個相當均衡的業務。這在我們目前以及未來在中國的業務中都扮演重要角色,而且我們與他們的關係非常穩固。

  • Anthony Petrone - Analyst

    Anthony Petrone - Analyst

  • And then a follow-up just on the distributor dynamic. With more limited visibility than we had in prior years, we’re going into the heightened season here in 2Q, 3Q. The visibility is still somewhat limited. So what is the right amount of inventory the distributors should be holding these days? And are your two distributors in the marketplace kind of where they need to be for where the end-market demand is? I’ll hop back in queue. Thanks.

    接著追問一下經銷商的動態。由於相較於過去幾年可見度更有限,我們正要進入第二季、第三季的旺季。目前可見度仍然有些有限。那麼,經銷商現在應該持有的合理庫存水位是多少?以及你們在市場上的兩家經銷商,就終端市場需求而言,庫存是否大致在應有的水位?我會回到隊列中。謝謝。

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Yeah. It’s a great one. We’ve said that six months is what we have contractual relationships with both of our importers, and we’re at or below those levels. So we were well beyond those as we exited 2024. We spent 2025 working them down painfully and made it through that process by the September timeframe, and now we’ve kept close watch on that.

    是的。這是一個很好的問題。我們之前說過,依合約我們與兩家進口商的合作關係所要求的庫存水位是六個月,而我們目前在該水位或更低。因此,在我們結束 2024 年時,庫存水位曾遠高於該標準。我們在 2025 年花了很多力氣、很痛苦地把它降下來,並在 9 月左右完成了這個過程,現在我們也一直密切監控。

  • Obviously, in-market demand remains the primary driver of how the inventory levels go up and down. But as Deborah pointed out earlier, the two-market sales now much more closely approximate the end-market demand that we’re seeing. So we have visibility of end market sales. It’s really logistics. We’ve disclosed around this extensively.

    顯然,市場端需求仍然是庫存水位上下變動的主要驅動因素。但如 Deborah 先前指出,現在兩個市場的銷售更貼近我們所看到的終端市場需求。因此,我們對終端市場銷售有能見度。這其實是物流問題。我們也已就此做過大量揭露。

  • But we talk about end-market sales, and what we’re talking about are the logistics. The shipments that go out from our importers downstream to sub-distributors, and in many cases, directly to hospitals, less those returns. And that gives us a really good approximation of what’s actually happening in the market. And as long as we continue to maintain our levels of inventory where we started, which is around or about six months, then we feel confident that we’ve got a good understanding of what’s happening with the end-market demand.

    但我們談到終端市場銷售時,實際上談的是物流。也就是從我們的進口商往下游出貨給次級經銷商,且在許多情況下直接出貨給醫院,扣除那些退貨。這讓我們能非常好地近似掌握市場上實際發生的情況。只要我們能持續把庫存維持在起始水位、也就是大約六個月左右,我們就有信心對終端市場需求的狀況有良好的理解。

  • Operator

    Operator

  • Ryan Zimmerman, BTIG.

    Ryan Zimmerman,BTIG。

  • Ryan Zimmerman - Analyst

    Ryan Zimmerman - Analyst

  • I’m going to keep hitting the same topic. I apologize because I think it’s very important. I look at the consignment numbers this quarter and last quarter, and I think about that in the context of where that’s been historically. I wanted to understand how you think about that because as the consignment does remain more elevated, I’m wondering how much of that is a reflection of your distributors, either some of that inventory coming back specifically and moving into consignment.

    我會繼續追問同一個主題。先道歉,因為我認為這非常重要。我看了本季與上季的寄售(consignment)數字,並把它放在歷史水準的脈絡下思考。我想了解你們如何看待這件事,因為寄售水位仍然偏高時,我在想其中有多少反映了你們的經銷商端,是否有部分庫存特別是回流後轉入寄售。

  • And then the ultimate question is, we’ve historically seen 1Q to 2Q step up. I don’t know if you’re committing to that. I can’t tell without the guidance, because again, in a normalized environment, you should see a step up from 1Q to 2Q in seasonal dynamics because of the busy season. But right now, the street is not modeling that.

    然後最終的問題是,我們過去通常會看到第 1 季到第 2 季的成長跳升。我不知道你們是否會承諾會如此。在沒有財測指引的情況下我無法判斷,因為在正常化的環境下,基於旺季的季節性動態,你應該會看到第 1 季到第 2 季的跳升。但目前市場共識並沒有把這點納入模型。

  • So I’m wondering if you could kind of help me think through the marriage of those two a little more closely. And this may be repetitive from what’s been asked, but it’s important, obviously.

    所以我想知道你們是否能幫我更緊密地把這兩者之間的關聯想清楚一些。這可能和先前問過的有點重複,但顯然這很重要。

  • Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

    Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

  • I mean, obviously we had a very, very strong Q1 and was probably even frankly a little more than what we were expecting, to be very honest with you. And so, our natural question is this going to duplicate in Q2? That’s the big question.

    我的意思是,很明顯我們第 1 季非常、非常強勁,坦白說甚至可能比我們原先預期的還要好一些。所以我們自然會問:第 2 季會不會再複製一次?這是最大的問題。

  • We expect to have a good Q2, as it is the beginning of the busy summer season. And whether it duplicates exactly or whether it’s a little bit more, we haven’t predicted at this time. We can’t predict at this time or we’re not predicting at this time.

    我們預期第 2 季會有不錯的表現,因為這是夏季旺季的開始。至於是否會完全複製,或是會再好一點,我們目前還沒有做出預測。我們目前無法預測,或是說我們目前不做預測。

  • And then Q3, again, it could be that the seasonal patterns change a little bit from what we’ve experienced historically. So we really need to -- we’ve had a good Q1, a clean Q1, I would say. And now we’re looking to repeat the trend here in Q3 and -- Q2 and 3 so that we’re able to predict on an accurate basis for you all.

    然後第 3 季,同樣地,季節性型態可能會和我們過去歷史經驗相比有些變化。所以我們真的需要——我們第 1 季表現很好,我會說是一個乾淨的第 1 季。現在我們希望在第 2 季以及——第 2、3 季把這個趨勢延續下去,這樣我們才能為各位做出更準確的預測。

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Yeah. And just on consignment inventory, Ryan. Thanks for the question. Look, we have some consignments around the world, ex-China, that help us maintain service levels for our business. We only put a consignment actually two different times, one consignment into China to avoid the impact of tariffs at the time when ultra-high -- if you go back and you remember 100%-plus tariffs, we shipped inventory proactively into China to be held at our importers.

    是的。另外就寄售庫存而言,Ryan。謝謝你的問題。你看,我們在全球(不含中國)有一些寄售安排,用來協助我們維持業務的服務水準。我們實際上只在兩個不同的時間點在中國做過一次寄售安排,目的是在當時為了避免關稅的影響——如果你回想一下、記得當時超高的關稅(超過 100%),我們曾主動把庫存先行運到中國,放在我們的進口商那裡。

  • But it wasn’t a move to a consignment strategy. That was a -- I sort of refer to it as a depleting amount of inventory. We don’t replenish it. So that consignment is sort of going away as it’s utilized, and we rely for service levels on our importers to have their inventory. So when we talk about inventory levels, it’s apples-for-apples that we required.

    但那並不是要轉向寄售策略。我把它稱作一個會逐步消耗的庫存量。我們不會補貨。因此,這個寄售庫存會隨著被使用而逐漸消失,而我們在服務水準上則仰賴進口商持有其庫存。所以當我們談庫存水位時,我們要求的是可直接對比(apples-for-apples)的水準。

  • We had a contract with our distributors to hold six months of inventory to maintain service levels. Well documented, we got us way outside of that. We got that back under control by September of last year and have maintained that, and that’s still true for Q1. And so, I wouldn’t conflate the consignment to particularly in China with any of those numbers.

    我們與經銷商有合約,要求持有六個月的庫存以維持服務水準。這點有充分紀錄,而那曾讓我們遠遠超出該水準。我們在去年 9 月前把它重新控制住並維持至今,而第 1 季也仍然如此。因此,我不會把寄售——特別是在中國的寄售——和那些數字混為一談。

  • Ryan Zimmerman - Analyst

    Ryan Zimmerman - Analyst

  • Okay. So second question -- go ahead, sorry. Thank you, Deb. Yes, appreciate that. Didn’t mean to interrupt. What is it that you need to see to give guidance? I mean, I guess, like, what are the metrics that you would look to and say, okay, now we have line of sight to our business. Because I think it’s not clear to us what’s holding you back given the performance we saw in 1Q, which was clearly good.

    好的。那第二個問題——請繼續,不好意思。謝謝你,Deb。是的,感謝你的說明。我不是要打斷。你們需要看到什麼才會給出指引?我的意思是,你們會看哪些指標,然後說,好,現在我們對業務有清楚的能見度了。因為在我們看來,考量到第 1 季的表現明顯很好,我們不太清楚是什麼讓你們卻步。

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Yeah, look, as I said before, I know why you want it. It makes perfect sense. And we'd love to give -- we tried to give some insights, particularly around OpEx, and we’ve even made comments around gross margin and so on.

    是的,你看,正如我之前說的,我知道你為什麼想要。這完全合理。我們也很希望能提供——我們已嘗試提供一些洞見,特別是在營運費用(OpEx)方面,我們甚至也對毛利率等做過一些評論。

  • The current structure, we’ve been in place now for four months. We’ve made a lot of progress, no doubt. Q1 strength is real. At the backdrop of everything that’s happening around the world and with the fact that others have sat here and said, hey, Q1 was great. Let’s raise -- let’s beat and raise and then give guidance, and then we watched how that turned out.

    目前的架構,我們到位至今才四個月。毫無疑問,我們已經取得了很大進展。第 1 季的強勁表現是真實的。在全球各種事情正在發生的背景下,而且也有其他公司坐在這裡說,嘿,第 1 季很棒。那就上修——那就超預期並上修,然後給出指引,接著我們也看到了結果如何。

  • And so, we’re pleased with Q1; we’re excited about Q2, but we’re just stopping short yet of giving it. As soon as we feel like we have enough stability to be able to accurately predict, because we want to be right. As soon as we feel like we have enough information to accurately predict for you is what we would need to have in order to provide it.

    因此,我們對第一季感到滿意;我們對第二季也很興奮,但目前還差一步,尚未提供指引。一旦我們覺得有足夠的穩定性可以做出準確預測,因為我們希望預測是正確的。一旦我們覺得掌握了足夠資訊,能夠為各位做出準確預測,那就是我們提供指引所需要具備的條件。

  • Operator

    Operator

  • David Saxon, Needham & Co.

    David Saxon,Needham & Co.

  • David Saxon - Equity Analyst

    David Saxon - Equity Analyst

  • Sorry to just harp on the second quarter. I just wanted to follow up, Deborah, on some of the comments you said. I think you said something like you expect to have a good 2Q. So just trying to understand, is that a reflection of trends you’re seeing in April and kind of into half of May? Even putting aside numbers, like anything qualitatively you can say or talk about how second quarter is shaping up relative to what we saw in the first quarter.

    抱歉一直緊抓第二季不放。Deborah,我只是想就你剛才的一些評論再追問一下。我記得你說過類似你預期第二季會不錯。所以我想了解一下,這是否反映了你們在四月以及延伸到五月上半月所看到的趨勢?即使先不談數字,有沒有任何定性層面的說法,或是可以談談第二季相較於第一季目前的成形狀況?

  • Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

    Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

  • I mean, second quarter is shaping up as I would expect in a normal Q2 based on historical trends.

    我的意思是,第二季的走勢就如同依據歷史趨勢在正常第二季會預期看到的那樣。

  • David Saxon - Equity Analyst

    David Saxon - Equity Analyst

  • Okay. That’s perfect. Thanks for that. And then maybe on just pricing. I mean, it looks like it was down maybe high single digits on a global basis. I don’t know if that’s just geographic mix or anything to call out there. And what are you seeing from a kind of region-specific basis on pricing? Thanks so much.

    好的。這樣就很完美了。謝謝你的說明。接著也許談一下定價。我的意思是,看起來全球層面可能下滑了高個位數百分比。我不確定這是否只是地理組合等因素,或有什麼需要特別指出的。那麼從各區域來看,你們在定價方面看到什麼情況?非常感謝。

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Yeah, thanks for the question. The whole world’s under pressure relative to pricing. I think we’ve done a pretty good job at the countries level of our leaders trying to hold pricing and get value for what is offering restorative sight to patients that are in search of it.

    好的,謝謝你的提問。在定價方面,全世界都承受壓力。我認為我們各國層級的主管在努力維持價格、並為我們所提供的「為尋求視力矯正的病患帶來恢復視力」的價值爭取合理回報方面,做得相當不錯。

  • So we’re proud of what folks have done. Sometimes you get nuances relative to the mix in Toric versus Sphere. That’s one thing that we keep an eye on. No doubt we’re getting an increase -- a lift in price in China with the launch of EVO+, which will help us from a global if you start averaging out ASPs.

    所以我們為同仁的表現感到自豪。有時候會出現一些與散光(Toric)與球面(Sphere)產品組合相關的細微差異。這是我們會持續關注的一點。毫無疑問,隨著EVO+在中國上市,我們在中國的價格會上升—帶來提價效應;若從全球角度把ASP平均起來,這將對我們有所幫助。

  • And then in various markets, as our customers start to go down the diopter curve and to choose lens-based refractive technology instead of laser-based that require removal of corneal tissue that’s not reversible, then those customers try and put pressure on us around price. And so, the hope is anywhere that we’re exchanging price, it’s in exchange for more volume, but it’s something we keep close tabs on.

    另外,在不同市場,當我們的客戶開始沿著屈光度曲線往下走,並選擇以晶體式屈光技術取代雷射式(需要移除不可逆的角膜組織)時,這些客戶就會在價格上對我們施加壓力。因此,我們希望任何我們做出價格交換的地方,都是以換取更高的量為前提;但這也是我們會密切追蹤的事項。

  • Mason Carrico, Stephens.

    Mason Carrico,Stephens。

  • Mason Carrico - Equity Analyst

    Mason Carrico - Equity Analyst

  • A lot’s been asked here, particularly around China, and I think you guys have made it clear that you don’t provide plan on providing some incremental insight there. But I wanted to ask, would you at least be willing to provide some additional thoughts around your expectation for growth in the business ex-China in 2026?

    大家問了很多問題,特別是關於中國;我想你們已經很清楚表示,你們不會、也沒有計畫提供更多額外的資訊。但我想問的是,你們是否至少願意就2026年中國以外(ex-China)業務的成長預期,提供一些額外看法?

  • And I guess as my second follow-up here, are you able to quantify the contribution from the expanded age range indication for EVO in the US?

    另外第二個追問,你們能否量化EVO在美國擴大適用年齡範圍適應症所帶來的貢獻?

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Hey, Mason. So maybe I’ll start with the second one first. We’ve quantified what the opportunity is. I think it’s a harder exercise to try and quantify exactly how much you get for it, especially in the first quarter when we received the updated labeling, which we’re excited about it. It matches most of the labeling we’ve had around the world.

    嗨,Mason。那我先從第二個問題開始。我們已經量化了這個機會有多大。但要精確量化它能帶來多少實際貢獻,是比較困難的,尤其是在第一季我們拿到更新標示(labeling)的時候;我們對此很興奮。它與我們在全球多數市場的標示內容相一致。

  • Our regulatory team is awesome, and they’ve done a great job of going and market by market looking to say, hey, where can we take advantage of getting more patients the potential to get EVO through our labeling? Whether it’s going down in age, whether it’s changing the cylinder, whether it’s just going down in the diopter that’s approved in that market. So kudos to that team.

    我們的法規團隊非常出色,他們做得很好,逐一市場去檢視並思考:嘿,我們可以在哪些地方透過標示內容,讓更多病患有機會使用EVO?不論是把適用年齡往下延伸、調整散光度數(cylinder),或只是把該市場核准的屈光度(diopter)範圍往下延伸。所以要給這個團隊掌聲。

  • It probably opens up a universe of 8 million more potential patients. We’ll see how many of those we can tackle over the course of the coming year and years. But we know it opens up. And it opens up more conversation around what are the options for patients. So there’s that.

    這可能會讓潛在病患的範圍再增加800萬人。接下來一年以及未來幾年,我們會看看能夠觸及其中多少人。但我們知道它確實擴大了市場。也會帶來更多關於病患有哪些選擇的討論。所以是這樣。

  • And then the first question, I’m sorry.

    然後第一個問題,不好意思。

  • Mason Carrico - Equity Analyst

    Mason Carrico - Equity Analyst

  • Growth expectations.

    成長預期。

  • Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

    Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

  • Ex-China?

    中國以外(ex-China)?

  • Mason Carrico - Equity Analyst

    Mason Carrico - Equity Analyst

  • Ex-China.

    中國以外(ex-China)。

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Look, we’re fighting it out. We remain optimistic, particularly in the long-term value of this business from a growth opportunity standpoint. If you just look at what’s happening with refractive surgery and the sluggishness that I described in the US, but also the shift that we’re seeing away from laser vision correction as the primary option, surgeons and customers and practices, depending on how they’re shaped around the world that are serious about offering refractive technologies must have EVO ICL as an offering in order for them to be a comprehensive refractive surgeon. And that is exciting for the long-term prospects of this business.

    你看,我們正在全力拚搏。我們仍然保持樂觀,特別是從成長機會的角度來看,這項業務的長期價值。如果你看看屈光手術的現況,以及我所描述美國市場的疲弱,同時也看到市場正從雷射視力矯正作為主要選項轉移;對於那些認真提供屈光技術的外科醫師、客戶與診所(視各國市場結構而定)而言,必須把EVO ICL納入其產品/服務組合,才能成為完整的屈光手術醫師。這讓我們對這項業務的長期前景感到振奮。

  • Now, in the short term, what role is ex-China going to play? We continue to have strong growth from major markets. You look at Japan, we’re proud of what’s happened there. You look at US, that’s a growing market, and it’s one we sort of stopped talking about, and we still are confident about the US as a long-term growth driver. The 22%-plus growth there coming off of a strong growth last year, and that number is now becoming a more respectable number. It used to be high growth on low volume.

    那麼短期來看,中國以外(ex-China)會扮演什麼角色?我們在主要市場仍持續有強勁成長。看看日本,我們對那裡的表現感到自豪。再看美國,那是一個成長中的市場;我們某種程度上不再特別談它,但我們仍然相信美國會是長期成長動能。在去年強勁成長的基礎上,美國仍有22%以上的成長,而這個數字現在正逐漸成為更「體面」的數字。以前是低基期下的高速成長。

  • Still want to grow that volume substantially, but we’re proud there and proud of other markets. We’ll keep fighting it out and do the best we can. But I think you’re going to see broad growth across the business.

    我們仍希望大幅提升那邊的量,但我們對那裡以及其他市場的表現感到自豪。我們會繼續全力拚搏,盡我們所能做到最好。但我認為你會看到整體業務呈現廣泛的成長。

  • Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

    Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

  • And we’re up pretty much in every market with the exception of the Middle East and India. So that hit us, as a result, our ex-China growth was only 6%. But it’s a solid 6% that’s great. It's pretty still mid-single digits. So if we get some relief in those other countries, other markets, then potentially, it could be higher than that.

    除了中東與印度之外,我們幾乎在每個市場都成長。因此受到影響,我們的中國以外(ex-China)成長只有6%。但這是很扎實的6%,而且很不錯。仍然大致是中個位數成長。所以如果那些國家、其他市場能稍微緩解一些壓力,那麼成長率有可能高於這個水準。

  • Operator

    Operator

  • Adam Maeder, Piper Sandler.

    Adam Maeder,Piper Sandler。

  • Adam Maeder - Senior Research Analyst

    Adam Maeder - Senior Research Analyst

  • Congrats on the start to the year. I’ll keep it to one. And Deborah, for you, wanted to ask about the P&L. I don’t think that’s been discussed yet in the Q&A. Really strong OpEx discipline in the quarter. Appreciate, I think you have the FY26 spend target of $225 million. Was hoping you could just maybe give us a little bit more color in terms of quarterly cadence for spend in the model.

    恭喜今年開局表現亮眼。我就問一個問題。Deborah,想請教你關於損益表(P&L)。我認為在問答環節中尚未討論到這點。本季營運費用(OpEx)控管非常出色。我知道你們對 FY26 的支出目標是 2.25 億美元。希望你能就模型中支出的季度節奏,提供更多一些說明。

  • And then on the gross margin front, maybe I just missed it in the prepared remarks, but can you just remind us how you expect gross margin to trend this year? Thank you.

    另外在毛利率方面,也許我在事先準備的發言中漏聽了,但能否提醒我們你們預期今年毛利率的走勢?謝謝。

  • Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

    Deborah Andrews - Interim Co-Chief Executive Officer, Chief Financial Officer

  • Right. Well, our targets for gross margin have been this year about 75%. We knew we’d fall short of that. I hope we exit the year -- at least exit the year at that. But we do have some headwinds with higher costed inventory rolling through the P&L, things like that. Inventory provisions, higher inventory provisions from expiring product that was sold in '23 and '24.

    好的。我們今年對毛利率的目標大約是 75%。我們知道會低於這個目標。我希望我們在年底時——至少在年底能達到那個水準。但我們確實面臨一些逆風,例如較高成本的庫存會逐步反映到損益表(P&L)中,諸如此類。還有庫存提列,因 2023 年與 2024 年售出的產品到期而導致更高的庫存提列。

  • And then we’re significantly increasing our volumes in our Swiss facility in the second half of the year. So with that, we should see improved unit costs in the second half of the year. And so, I hope you’ll see tailwinds on gross margin beginning in 2027. That’s the target for gross margin overall.

    此外,我們在今年下半年將大幅提高瑞士廠的產量。因此,我們應該會在下半年看到單位成本改善。所以,我希望你們會在 2027 年開始看到毛利率的順風。這就是整體毛利率的目標。

  • In terms of spending, our spending is fairly linear with the exception of when we have trade shows. So in quarters where we have trade shows like ASCRS or ESCRS, which is typically like Q2, Q3, you’ll see a bump in spending. Otherwise -- and it just depends. We're actually spending this year, if you multiply it out, it’s well under $225 million run rate.

    就支出而言,除了有展會的時候之外,我們的支出相當線性。因此,在有展會的季度,例如 ASCRS 或 ESCRS(通常在第二季、第三季),你會看到支出上升。除此之外——而且也要看情況。其實我們今年的支出,如果按年化推算,遠低於 2.25 億美元的運行率。

  • So we do expect that there will be some increased DTC and things like that in the following quarters. So it’s not going to be exactly the same. I expect it’s just going to increase from where it is, but overall, maintain that $225 million level.

    因此,我們確實預期接下來幾季會增加一些 DTC(直面消費者)等方面的投入。所以不會完全一樣。我預期會在目前水準之上有所增加,但整體仍維持在 2.25 億美元這個水準。

  • Operator

    Operator

  • Anthony Petrone, Mizuho Group.

    Anthony Petrone,瑞穗集團(Mizuho Group)。

  • Anthony Petrone - Analyst

    Anthony Petrone - Analyst

  • You’ve given out in the past just the global growth rate of the refractive market, total refractive surgeries. And then if we have to break that out, I guess globally, we can do the math just where ICL sits. But do you have handy the where we exited April as it relates to global refractive surgery growth and where are you guys settling up versus that? Thanks.

    你們過去曾提供全球屈光市場的成長率,也就是屈光手術總量。如果需要拆分來看,我想在全球範圍內,我們可以自行推算 ICL 所處的位置。但你們手邊是否有截至 4 月底的全球屈光手術成長情況,以及你們相對於該成長率目前的表現如何?謝謝。

  • Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

    Warren Foust - President, Interim Co-Chief Executive Officer, Chief Operating Officer

  • Thanks, Anthony. Those numbers are just so muddy. When you get outside of the US and outside of Western Europe and just a few countries, and then outside of major markets, China, Japan, it gets pretty muddy. Market Scope does a good job, the best they can. IQVIA Data does the best job they can.

    謝謝你,Anthony。那些數據真的非常混雜。當你走出美國、走出西歐以及少數幾個國家,再走出主要市場(中國、日本)之後,數據就變得相當混亂。Market Scope 已經盡其所能做得很好。IQVIA 的數據也已經盡其所能做到最好。

  • Refractive Surgery Council in the US would tell you that the first quarter was down 7%. We grew 22%. Last year, I think they would say it was down 15%. The China market, who knows? It looks like it was flattish, at least for the last year or so. And you see what we’re doing in growth. Our growth numbers are sort of gaudy, obviously, because of the low base or no base even in Q1. And so, that’s not appropriate.

    美國的屈光手術委員會(Refractive Surgery Council)會告訴你第一季下滑 7%。我們成長了 22%。去年,我想他們會說下滑了 15%。中國市場呢,誰知道?看起來至少在過去一年左右是持平。而你也看到我們的成長表現。我們的成長數字看起來有點誇張,顯然是因為基期很低,甚至第一季幾乎沒有基期。因此,那樣的比較並不恰當。

  • But I think what we believe is happening is what others have said is happening, including our largest customer, that the market’s sort of stable. Maybe it’s low single digits. Could be even flat, and maybe we’re getting it out of price with EVO+.

    但我認為我們相信正在發生的情況,與其他人所說的一致,包括我們最大的客戶也這麼說:市場大致上是穩定的。也許是低個位數成長。甚至可能持平,而我們或許是透過 EVO+ 的定價來取得成長。

  • It’s just too early to tell on what’s happening there. But I think if you just take a step back from it and you acknowledge that the data is dirty, the laser vision correction market is flat to declining in most major markets around the world. Where SMILE has a larger penetration of the total laser vision correction procedures, then they grow a little bit. But generally speaking, the refractive market is pulled down by lasers, and it’s increasing by ICLs.

    目前要判斷那邊的情況還太早。但我認為如果你退一步看,並承認數據不夠乾淨,那麼在全球多數主要市場,雷射視力矯正市場是持平到下滑的。在 SMILE 於整體雷射視力矯正手術中的滲透率較高的地方,市場會成長一些。但總體而言,屈光市場被雷射所拖累,而 ICL 則帶動成長。

  • Operator

    Operator

  • This concludes our question-and-answer session as well as conference call. Thank you for attending today’s presentation. You may now disconnect.

    我們的問答環節以及本次電話會議到此結束。感謝各位參加今天的簡報。您現在可以掛線。